Sanofi's Sarclisa Scores In Myeloma But Is Still In Darzalex’s Shadow

Best PFS In Second Line Setting

 
• By Andrew McConaghie
  
Sanofi Lyon
Sanofi's Sarclisa is taking on the $6bn-a-year blockbuster Darzalex. • Source: Alamy
Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

SpotifyApple PodcastsWebsite

More from Business

More from Scrip